Kiniksa Pharmaceuticals International (KNSA) reported Q1 net income Tuesday of $0.11 per diluted share, swinging from a loss of $0.25 a year earlier.
Analysts polled by FactSet expected $0.13.
Revenue for the quarter ended March 31 was $137.8 million, up from $79.9 million a year earlier.
Analysts surveyed by FactSet expected $131.9 million.
For 2025, the life sciences company lifted its net product revenue expectation to a range of $590 million to $605 million, from between $560 million and $580 million.
Shares of the company were up 4.8% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.